Spero Therapeutics (NASDAQ:SPRO) Upgraded by Zacks Research to “Hold” Rating

Posted by on Sep 16th, 2026

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued on Monday, Zacks reports.

SPRO has been the subject of a number of other research reports. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a research note on Monday. Weiss Ratings raised shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. Finally, HC Wainwright raised their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Spero Therapeutics has a consensus rating of “Hold” and an average target price of $6.00.

Get Our Latest Stock Analysis on SPRO

Spero Therapeutics Price Performance

SPRO stock opened at $1.13 on Monday. The business’s 50-day moving average is $1.32 and its two-hundred day moving average is $2.10. The firm has a market capitalization of $65.81 million, a P/E ratio of 10.27 and a beta of 1.49. Spero Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.08.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, analysts expect that Spero Therapeutics will post -0.58 EPS for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SPRO. Alphabet Inc. acquired a new stake in Spero Therapeutics during the second quarter worth approximately $1,967,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics during the 2nd quarter worth approximately $1,314,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $36,000. Global Retirement Partners LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $55,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Spero Therapeutics in the 2nd quarter valued at $632,000. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

Read More

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.